Vical (Nasdaq: VICL) reported earnings on Feb. 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Vical missed estimates on revenues and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped significantly, and GAAP loss per share stayed the same.

Margins dropped across the board.

Revenue details
Vical tallied revenue of $1.9 million. The five analysts polled by S&P Capital IQ predicted revenue of $2.0 million. GAAP sales were 34% lower than the prior-year quarter's $2.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.09. The four earnings estimates compiled by S&P Capital IQ anticipated -$0.12 per share. GAAP EPS of -$0.09 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was -33.0%, 3,380 basis points worse than the prior-year quarter. Operating margin was -364.7%, 12,040 basis points worse than the prior-year quarter. Net margin was -342.3%, 11,050 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $3.5 million. On the bottom line, the average EPS estimate is -$0.11.

Next year's average estimate for revenue is $16.6 million. The average EPS estimate is -$0.39.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 154 members rating the stock outperform and 11 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Vical a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vical is outperform, with an average price target of $6.75.

The biotechnology and healthcare investing landscape is littered with also-rans and a few major winners. Is Vical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.